Page 56 - Программа - Всероссийский конгресс с международным участием «Нейронауки: интеграция теории и практики», 18-19 ноября 2022 года, Онлайн

Известия Российской
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ Том 41, № 4, 2022 Военно-медицинской академии
405
11. Kennedy S.H., Evans K.R., Krüger S., et al. Changes in regional 16. Li J., Ouyang W. Application of PET Imaging in the Brain Re-
brain glucose metabolism measured with positron emission tomog- gions of the Emotional Control Loop in Patients with Generalized
raphy after paroxetine treatment of major depression // Am. J. Psy- Anxiety Disorder // J Healthc Eng. 2021. Vol. 2021. Art. 4505227.
chiatry. 2001. Vol. 158. P. 899–905. DOI: 10.1176/appi.ajp.158.6.899 DOI: 10.1155/2021/4505227
12. Mayberg H.S., Brannan S.K., Tekell J.L., et al. Regional meta- 17. Wu J.C., Buchsbaum M.S., Hershey T.G., et al. PET in gener-
bolic effects of fluoxetine in major depression: Serial changes and alized anxiety disorder // Biol. Psychiatry. 1991. Vol. 29, No. 12.
relationship to clinical response // Biol. Psychiatry. 2000. Vol. 48. P. 1181–1199. DOI: 10.1016/0006-3223(91)90326-h
P. 830–843. DOI: 10.1016/s0006-3223(00)01036-2 18. Shah N.N., Schwandt M.L., Hobden B., et al. The validity of the
13. De Asis J.M., Silbersweig D.A., Pan H., et al. Neuro- state-trait anxiety inventory and the brief scale for anxiety in an in-
imaging studies of fronto-limbic dysfunction in geriatric de- patient sample with alcohol use disorder // Addiction. 2021. Vol. 116,
pression // Clin. Neurosci. Res. 2003. Vol. 2. P. 324–330. No. 11. P. 3055–3068. DOI: 10.1111/add.15516
DOI: 10.1016/s1566-2772(03)00009-4 19. Passik S.D., Kirsh K.L., Donaghy K.B., et al. An attempt to em-
18
14. Fu C, Zhang H, Xuan A, et al. A combined study of F-FDG PET-CT ploy the Zung Self-Rating Depression Scale as a “lab test” to trigger
and fMRI for assessing resting cerebral function in patients with follow-up in ambulatory oncology clinics: criterion validity and detec-
major depressive disorder // Exp. Ther. Med. 2018. Vol. 16, No. 3. tion // J. Pain Symptom Manage. 2001. Vol. 21, No. 4. P. 273–281.
P. 1873–1881. DOI: 10.3892/etm.2018.6434 DOI: 10.1016/s0885-3924(00)00264-5
15. Horti A.G., Naik R., Foss C.A., et al. PET imaging of microglia by 20. Northoff G., Zilio F. Temporo-spatial Theory of Conscious-
targeting macrophage colony-stimulating factor 1 receptor (CSF1R) \\ ness (TTC) — Bridging the gap of neuronal activity and phe-
Proc. Natl. Acad. Sci. U S A. 2019. Vol. 116, No. 5. P. 1686–1691. nomenal states // Behav. Brain Res. 2022. Vol. 424. Art. 113788.
DOI: 10.1073/pnas.1812155116 DOI: 10.1016/j.bbr.2022.113788

REFERENCES
1. Lovelace DL, McDaniel LR, Golden D. Long-Term Effects of after paroxetine treatment of major depression. Am J Psychiatry.
Breast Cancer Surgery, Treatment, and Survivor Care. J Midwifery 2001;158:899–905. DOI: 10.1176/appi.ajp.158.6.899
Womens Health. 2019;64(6):713–724. DOI: 10.1111/jmwh.13012. 12. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic
2. Shah C, Arthur D, Riutta J, et al. Breast-cancer related lymph- effects of fluoxetine in major depression: Serial changes and re-
edema: A review of procedure-specific incidence rates, clinical as- lationship to clinical response. Biol Psychiatry. 2000;48:830–843.
sessment aids, treatment paradigms, and risk reduction. Breast DOI: 10.1016/s0006-3223(00)01036-2
Journal. 2012;18(4):357–361. DOI: 10.1111/j.1524–4741.2012.01252.x 13. 13.De Asis JM, Silbersweig DA, Pan H, et al. Neuroimaging stud-
3. Tsaras K, Papathanasiou IV, Mitsi D, et al. Assessment of De- ies of fronto-limbic dysfunction in geriatric depression. Clin Neurosci
pression and Anxiety in Breast Cancer Patients: Prevalence and As- Res. 2003;2:324–330. DOI: 10.1016/s1566-2772(03)00009-4
sociated Factors. Asian Pac J Cancer Prev. 2018;19(6):1661–1669. 14. Fu C, Zhang H, Xuan A, et al. A combined study of F-FDG PET-CT
18
DOI: 10.22034/apjcp.2018.19.6.1661 and fMRI for assessing resting cerebral function in patients with
4. Yi JC, Syrjala KL. Anxiety and Depression in Can- major depressive disorder. Exp Ther Med. 2018;16(3):1873–1881.
cer Survivors. Med Clin North Am. 2017;101(6):1099–1113. DOI: 10.3892/etm.2018.6434
DOI: 10.1016/j.mcna.2017.06.005 15. Horti AG, Naik R, Foss CA, et al. PET imaging of microg-
5. Crane TE, Badger TA, Sikorskii A, et al. Trajectories of Depression lia by targeting macrophage colony-stimulating factor 1 recep-
and Anxiety in Latina Breast Cancer Survivors. Oncol Nurs Forum.
tor (CSF1R). Proc Natl Acad Sci USA. 2019;116(5):1686–1691.
2019;46(2):217–227. DOI: 10.1188/19.ONF.217-227 DOI: 10.1073/pnas.1812155116
6. Gong Y, Tan Q, Qin Q, et al. Prevalence of postmastectomy 16. Li J, Ouyang W. Application of PET Imaging in the Brain Regions of
pain syndrome and associated risk factors: A large single-insti-
the Emotional Control Loop in Patients with Generalized Anxiety Dis-
tution cohort study. Medicine (Baltimore). 2020;99(20): e19834.
DOI: 10.1097/MD.0000000000019834 order. J Healthc Eng. 2021;2021:4505227. DOI: 10.1155/2021/4505227
7. Jensen MP, Chang HY, Lai YH, et al. Pain in long-term breast 17. Wu JC, Buchsbaum MS, Hershey TG, et al. PET in general-
ized anxiety disorder. Biol Psychiatry. 1991;29(12):1181–1199.
cancer survivors: frequency, severity, and impact. Pain Med.
2010;11(7):1099–1106. DOI: 10.1111/j.1526-4637.2010.00880.x DOI: 10.1016/0006-3223(91)90326-h
8. Liu Z, Xu C, Xu Y, et al. Decreased regional homogeneity in insula 18. Shah NN, Schwandt ML, Hobden B, et al. The validity of the
state-trait anxiety inventory and the brief scale for anxiety in an in-
and cerebellum: A resting-state fMRI study in patients with major
depression and subjects at high risk for major depression. Psychiatry patient sample with alcohol use disorder. Addiction. 2021;116(11):
Res. 2010;182(3):211–215. DOI: 10.1016/j.pscychresns.2010.03.004 3055–3068. DOI: 10.1111/add.15516
9. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic 19. Passik SD, Kirsh KL, Donaghy KB, et al.An attempt to employ the
study of changes in brain activation in depression. Hum Brain Mapp. Zung Self-Rating Depression Scale as a “lab test” to trigger follow-up in
2008;29:683–695. DOI: 10.1002/hbm.20426 ambulatory oncology clinics: criterion validity and detection. J Pain Symp-
10. Guo WB, Sun XL, Liu L, et al.. Disrupted regional homogeneity tom Manage. 2001;21(4):273–281. DOI: 10.1016/s0885-3924(00)00264-5
in treatment-resistant depression: A resting-state fMRI study. Prog 20. Northoff G, Zilio F. Temporo-spatial Theory of Conscious-
Neuropsychopharmacol Biol Psychiatry. 2011;35:1297–1302. ness (TTC) — Bridging the gap of neuronal activity and phe-
11. Kennedy SH, Evans KR, Krüger S, et al. Changes in regional brain nomenal states. Behavioural Brain Research. 2022;424:113788.
glucose metabolism measured with positron emission tomography DOI: 10.1016/j.bbr.2022.113788
DOI: https://doi.org/10.17816/rmmar111887